Details of the BTS
General Information of Binding Target of SBP (BTS) (ID: ST00033) | ||||||
---|---|---|---|---|---|---|
BTS Name |
Vascular endothelial growth factor receptor 2
|
|||||
Synonyms |
VEGFR-2; EC 2.7.10.1; Fetal liver kinase 1; FLK-1; Kinase insert domain receptor; KDR; Protein-tyrosine kinase receptor flk-1; CD antigen CD309
|
|||||
BTS Type |
Protein
|
|||||
Family |
Protein kinase superfamily;
Tyr protein kinase family; CSF-1/PDGF receptor subfamily |
|||||
Gene Name |
KDR
|
|||||
Organism |
Homo sapiens (Human)
|
|||||
Function |
Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD. Isoform 2 plays an important role as negative regulator of VEGFA- and VEGFC-mediated lymphangiogenesis by limiting the amount of free VEGFA and/or VEGFC and preventing their binding to FLT4. Modulates FLT1 and FLT4 signaling by forming heterodimers. Binding of vascular growth factors to isoform 1 leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, reorganization of the actin cytoskeleton and activation of PTK2/FAK1. Required for VEGFA-mediated induction of NOS2 and NOS3, leading to the production of the signaling molecule nitric oxide (NO) by endothelial cells. Phosphorylates PLCG1. Promotes phosphorylation of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1 and SRC.
|
|||||
UniProt ID | ||||||
UniProt Entry | ||||||
PFam | ||||||
Gene ID | ||||||
Sequence |
MQSKVLLAVALWLCVETRAASVGLPSVSLDLPRLSIQKDILTIKANTTLQITCRGQRDLD
WLWPNNQSGSEQRVEVTECSDGLFCKTLTIPKVIGNDTGAYKCFYRETDLASVIYVYVQD YRSPFIASVSDQHGVVYITENKNKTVVIPCLGSISNLNVSLCARYPEKRFVPDGNRISWD SKKGFTIPSYMISYAGMVFCEAKINDESYQSIMYIVVVVGYRIYDVVLSPSHGIELSVGE KLVLNCTARTELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDGVTRS DQGLYTCAASSGLMTKKNSTFVRVHEKPFVAFGSGMESLVEATVGERVRIPAKYLGYPPP EIKWYKNGIPLESNHTIKAGHVLTIMEVSERDTGNYTVILTNPISKEKQSHVVSLVVYVP PQIGEKSLISPVDSYQYGTTQTLTCTVYAIPPPHHIHWYWQLEEECANEPSQAVSVTNPY PCEEWRSVEDFQGGNKIEVNKNQFALIEGKNKTVSTLVIQAANVSALYKCEAVNKVGRGE RVISFHVTRGPEITLQPDMQPTEQESVSLWCTADRSTFENLTWYKLGPQPLPIHVGELPT PVCKNLDTLWKLNATMFSNSTNDILIMELKNASLQDQGDYVCLAQDRKTKKRHCVVRQLT VLERVAPTITGNLENQTTSIGESIEVSCTASGNPPPQIMWFKDNETLVEDSGIVLKDGNR NLTIRRVRKEDEGLYTCQACSVLGCAKVEAFFIIEGAQEKTNLEIIILVGTAVIAMFFWL LLVIILRTVKRANGGELKTGYLSIVMDPDELPLDEHCERLPYDASKWEFPRDRLKLGKPL GRGAFGQVIEADAFGIDKTATCRTVAVKMLKEGATHSEHRALMSELKILIHIGHHLNVVN LLGACTKPGGPLMVIVEFCKFGNLSTYLRSKRNEFVPYKTKGARFRQGKDYVGAIPVDLK RRLDSITSSQSSASSGFVEEKSLSDVEEEEAPEDLYKDFLTLEHLICYSFQVAKGMEFLA SRKCIHRDLAARNILLSEKNVVKICDFGLARDIYKDPDYVRKGDARLPLKWMAPETIFDR VYTIQSDVWSFGVLLWEIFSLGASPYPGVKIDEEFCRRLKEGTRMRAPDYTTPEMYQTML DCWHGEPSQRPTFSELVEHLGNLLQANAQQDGKDYIVLPISETLSMEEDSGLSLPTSPVS CMEEEEVCDPKFHYDNTAGISQYLQNSKRKSRPVSVKTFEDIPLEEPEVKVIPDDNQTDS GMVLASEELKTLEDRTKLSPSFGGMVPSKSRESVASEGSNQTSGYQSGYHSDDTDTTVYS SEEAELLKLIEIGVQTGSTAQILQPDSGTTLSSPPV |
|||||
Sequence Length |
1356
|
|||||
Synthetic Binding Protein (SBP) Targeting This BTS |
---|
SBP Name | Highest Status | Mechanism | Affinity | Application | Details | Ref |
---|---|---|---|---|---|---|
Affimer anti-VEGFR-2 A9 | Research | Inhibitor | Kd: 41 nM | Tools for modulators of protein function;tools for affinity histochemistry | [1] | |
Affimer anti-VEGFR-2 B8 | Research | Inhibitor | Kd: 240 nM | Tools for modulators of protein function;tools for affinity histochemistry | [1] | |
DARPin anti-VEGFR-2 D23b | Research | Inhibitor | Kd: 0.01 nM | Diagnostic reagent | [2], [3] | |
DARPin anti-VEGFR-2 D4b | Research | Inhibitor | Kd: 0.19 nM | Diagnostic reagent | [2], [3] | |
DARPin anti-VEGFR-2 D7b | Research | Inhibitor | Kd: 0.37 nM | Diagnostic reagent | [2], [3] | |
Fab Alacizumab | Phase II | Antagonist | N.A. | Non-small cell lung cancer [ICD-11: 2C25.Y] | [4] | |
Monobody anti-VEGFR-2 | Research | Binder | Kd: 0.72 nM | Research tool | [5] | |
Monobody anti-VEGFR-2 pAdHM72-alphaV-L2 | Research | Inhibitor | Kd: 1.2 nM | Targeted gene therapy | [6] | |
Monobody Pegdinetanib | Phase II | Inhibitor | Kd: 11 nM | Pancreatic cancer [ICD-11: 2C10.Z]; Non-Hodgkin lymphoma [ICD-11: 2B33.5]; Macular degeneration [ICD-11: 9B78.3Z]; Glioblastoma [ICD-11: XH7F82]; Colorectal cancer [ICD-11: 2B91.Z]; Non-small cell lung cancer [ICD-11: 2C25.Y] | [7], [8], [9] | |
Nanobody anti-VEGFR-2 NTV1 | Research | Inhibitor | Kd: 49 nM | Cancers [ICD-11: 2D4Z] | [10] | |
Nanobody anti-VEGFR-2 NTV2 | Research | Binder | N.A. | Cancers [ICD-11: 2D4Z] | [10] | |
Nanobody anti-VEGFR-2 NTV3 | Research | Binder | N.A. | Cancers [ICD-11: 2D4Z] | [10] | |
Nanobody anti-VEGFR-2 NTV4 | Research | Binder | N.A. | Cancers [ICD-11: 2D4Z] | [10] | |
WW domain anti-VEGFR-2 clone B1 | Research | Binder | Kd: 44 nM | Research tool | [11] | |
WW domain anti-VEGFR-2 cycB1_4-28 | Research | Binder | Kd: 35 nM | Research tool | [11] | |
WW domain anti-VEGFR-2 cycB1_6-36 | Research | Binder | Kd: 67 nM | Research tool | [11] | |
References |
---|